

WEDNESDAY, JULY 8 2026, MORNING SESSIONS

6:00 AM **BREAKFAST**

WELCOME & KEYNOTES

6:30 AM	Welcome & Introductions	<i>Vinay Jain</i>
6:45 AM	Keynote: Lessons learned — my life journey	<i>Ravi Salgia</i>
6:55 AM	The long journey of attitudes and treatment approaches for head and neck cancer	<i>Everett Vokes</i>

7:05 AM **DISCUSSION**

DRUGS TARGETING EGFR AND MET

John Heymach

7:20 AM	Evaluating the impact of EGFR expression and location on the efficacy of therapy	<i>Matthew Lee</i>
7:27 AM	APO pathway (AICDA/cytidine deamination) as a mechanism of on-target EGFR resistance	<i>Khaled Hassan</i>
7:34 AM	EGFR resistance in NSCLC: How to decide what comes next	<i>Julia Rotow</i>
7:41 AM	Subcutaneous amivantamab (PALOMA-2): Is subQ not just easier but pharmacodynamically better?	<i>Natasha Leigh</i>
7:48 AM	Amivantamab for treatment of MET-amplified relapsed/refractory NSCLC	<i>Richard Hall</i>
7:55 AM	Development of an AI model to identify patients who will respond to EGFR-targeted monotherapy vs combination regimens	<i>Fionnuala Crowley</i>
8:02 AM	ADCs targeting MET (Teliso-V and Teliso-A)	<i>Timothy Burns</i>
8:09 AM	Amivantamab: Strategic approaches to improving outcomes and tolerance	<i>Helen Ross</i>

8:16 AM **DISCUSSION**

OPTIMIZING TARLATAMAB IN THE TREATMENT SETTING

Millie Das

8:35 AM	Tarlatamab as a monotherapy for frontline treatment of SCLC	<i>Asrar Alahmadi</i>
8:42 AM	Outcomes from real-world experience with tarlatamab in SCLC	<i>Richard Hall</i>
8:49 AM	Findings from a retrospective analysis of tarlatamab safety and efficacy in a population of SCLC patients in the VA system	<i>Michael Kelley</i>
8:56 AM	Transcription factor subtype governs response and resistance to tarlatamab	<i>Matthew Oser</i>

9:03 AM **DISCUSSION**

HER2 KINASE INHIBITORS AND ADCs FOR HER2/HER3 IN NSCLC

Misako Nagasaka

9:25 AM	Recent data with Zongertinib in newly diagnosed HER2-Mutant Non-Small-Cell Lung Cancer	<i>Joshua Sabari</i>
9:32 AM	Sevabertinib in previously treated HER2 mutated NSCLC	<i>Xiuning Le</i>
9:39 AM	Comprehensive structural/ resistance dataset across all HER2 drugs	<i>John Heymach</i>
9:46 AM	HER2-selective TKI with CNS penetration; spares WT EGFR (NVL-330)	<i>Xiuning Le</i>

9:53 AM **DISCUSSION**

10:10 AM **BREAK AND GROUP PHOTO**

K-RAS G12C TARGETING AGENTS

Ferdinandos Skoulidis

10:30 AM	Sotorasib in G12C mutant NSCLC: The VA experience	<i>Michael Kelley</i>
10:37 AM	Update on adagrasib plus pembrolizumab combination in KRAS G12C NSCLC	<i>Sulin Wu</i>
10:44 AM	Olomorasib + pembrolizumab +/- chemotherapy in KRAS G12C-mutant NSCLC	<i>Umit Tapan</i>
10:51 AM	Intracranial efficacy of olomorasib, in KRAS G12C-mutant NSCLC with untreated brain metastases	<i>Timothy Burns</i>

10:58 AM **DISCUSSION**

EGFR INHIBITORS IN ADJUVANT AND NEOADJUVANT SETTINGS

Jay Lee

11:15 AM	Lessons learned from NeoADAURA and how to implement osimertinib in the neoadjuvant space	<i>Jamie Chافت</i>
11:22 AM	Findings from a clinical trial of neoadjuvant osimertinib prior to chemoradiation in EGFR+ NSCLC	<i>Jacqueline Aredo</i>
11:29 AM	Role of consolidation in EGFR mutant oligometastatic disease	<i>Urs Weber</i>
11:36 AM	Zipalertinib, a TKI targeting EGFR exon 20 and PACC mutations in the neoadjuvant setting for NSCLC	<i>Arjan Gower</i>

11:43 AM **DISCUSSION**

EMERGING DLL3-TARGETING AGENTS IN SCLC

Lauren Byers

12:00 PM	Obrixtamig (BI 764532): A DLL3 x CD3 bispecific	<i>Joshua Sabari</i>
12:07 PM	A trispecific mAb with CD3 and a biparatopic DLL3 binding in SCLC and data from the PRESERVE-003 trial	<i>Zhonglin Hao</i>
12:14 PM	ZG006, a trispecific with targeting of CD3 and biparatopic targeting of DLL3 in SCLC	<i>Bingnan Zhang</i>
12:21 PM	Current data for IBI3009, an anti-DLL3 ADC in development for advanced SCLC and other neuroendocrine tumors	<i>Zhaohui Arter</i>
12:28 PM	An overview of directed therapy with actinium in SCLC (ABD-147 and RYZ101)	<i>Bingnan Zhang</i>

12:35 PM **DISCUSSION**

WEDNESDAY, JULY 8 2026, AFTERNOON SESSIONS

12:50 PM	WORKING LUNCH SESSION : INDUSTRY PIPELINE PRESENTATIONS	<i>Vinay Jain</i>
1:10 PM	Johnson & Johnson	<i>Joshua Bauml</i>
1:20 PM	Boehringer Ingelheim	<i>Audra Kammerer</i>
1:30 PM	Pfizer Oncology	<i>TBD</i>
1:40 PM	Jazz Pharmaceuticals	<i>TBD</i>
1:50 PM	Eli Lilly	<i>TBD</i>
PERIOPERATIVE THERAPY <i>John Heymach</i>		
2:05 PM	Neoadjuvant therapy approaches for stage III non-small cell lung cancer	<i>Everett Vokes</i>
2:12 PM	Ultra-sensitive ctDNA MRD approaches for treatment optimization in resectable NSCLC	<i>Valsamo Anagnostou</i>
2:19 PM	ctDNA in stage I disease	<i>Natasha Leighl</i>
2:26 PM	My experience with post-targeted therapy resection in lung cancer	<i>Erin Gillaspie</i>
2:33 PM	An update on surgical interventions in the NORTHSTAR trial	<i>Mara Antonoff</i>
2:40 PM	Using ctDNA to guide radiation discontinuation for patients with head and neck cancer	<i>Jonathan Schoenfeld</i>
2:47 PM	DISCUSSION	
CHECKPOINT INHIBITORS IN NSCLC <i>Heather Wakelee</i>		
3:05 PM	Optimizing immune checkpoint therapy in perioperative therapy for NSCLC	<i>Henry Park</i>
3:12 PM	A multiomic analysis to assess mechanisms of resistance to immune checkpoint inhibition in NSCLC	<i>Valsamo Anagnostou</i>
3:19 PM	Long-term and late toxicities in survivors post-checkpoint inhibitors — cardiac disease and beyond	<i>Melinda Hsu</i>
3:26 PM	Outpatient monitoring for detection of ICI-induced pneumonitis	<i>Antonious Hazim</i>
3:33 PM	MDT-BRIDGE, neoadjuvant durvalumab + platinum- chemotherapy stage IIB-IIIB NSCLC	<i>Stephen Swisher</i>
3:40 PM	The potential role of multi-site SBRT with immune checkpoint inhibitors for first line metastatic NSCLC	<i>Aditya Juloori</i>
3:47 PM	DISCUSSION	

THURSDAY, JULY 9, 2026, MORNING SESSIONS

6:00 AM **BREAKFAST**

SURGICAL CONSIDERATIONS

Stephen Swisher

6:30 AM	The role of lung transplantation in lung cancer: A 2026 perspective	<i>Marc de Perrot</i>
6:37 AM	Considerations for lung cancer in the younger population, including aggressive surgical approaches	<i>Mara Antonoff</i>
6:44 AM	Advances in diagnosis and staging of lung cancer using robotic bronchoscopy	<i>Matthew Bott</i>
6:51 AM	How do we incorporate ctDNA and PET into cancer staging?	<i>James Huang</i>
6:58 AM	Resectability guidelines: How do they help us, and what are we missing?	<i>Erin Gillaspie</i>
7:05 AM	Minimally invasive techniques for treating early stage lung cancer	<i>Matthew Bott</i>
7:12 AM	DISCUSSION	

TARGETING ALK

Ravi Salgia

7:30 AM	Using a clinical ALK+ database to improve enrollment approaches to clinical trials for ALK-targeted therapy	<i>Ken Culver</i>
7:37 AM	Lorlatinib updated 7-year update from the phase 3 CROWN study.	<i>Misako Nagasaka</i>
7:44 AM	Neoadjuvant lorlatinib and alectinib in stage III NSCLC harboring ALK fusion	<i>Jay Lee</i>
7:51 AM	Neladalkib, with activity against diverse ALK fusions and resistance mutations in NSCLC	<i>Elaine Shum</i>
7:58 AM	A patient's perspective:	<i>Marc Muskavitch</i>
8:05 AM	DISCUSSION	

SCLC - IMMUNOTHERAPY

John Heymach

8:20 AM	From Four Subtypes to One Clear Path: The Future of Personalized SCLC Care	<i>Lauren Byers</i>
8:27 AM	IMforte: The role of atezolizumab + lurbinectedin in frontline SCLC	<i>Jeff Petty</i>
8:34 AM	Biomarker discovery: ISL1 predicts strong responses to a lurbinectedin	<i>Misty Shields</i>
8:41 AM	LB2102, an anti-DLL3 CAR T in development for SCLC	<i>Bingnan Zhang</i>
8:48 AM	BMS 986489 (fucosylated anti-GM1 mAb) + nivolumab in the TIGOS trial for ES-SCLC	<i>Sid Devarakonda</i>
8:55 AM	Inhibitors of cyclin A and B and synthetic lethality in RB-deficient SCLC (CID-078)	<i>Matthew Oser</i>
9:02 AM	Emerging data for gotistobart (BNT316/ONC392), a novel pH-activated anti-CTLA4 for SCLC	<i>Zhonglin Hao</i>
9:09 AM	DISCUSSION	

9:25 AM **BREAK**

TROP2-TARGETED ADCs IN LUNG CANCER

Joshua Sabari

9:35 AM	Biomarkers for Antibody-Drug Conjugates — Trop-2 NMR, QCS, and the HER2 confusion in lung cancer	<i>Fred Hirsch</i>
9:42 AM	Ongoing clinical trials with datopotamab deruxtecan in EGFR-mutant NSCLC	<i>Jonathan Riess</i>
9:49 AM	Current data with sacituzumab govitecan in NSCLC	<i>Sandip Patel</i>
9:56 AM	Outcomes with sacituzumab govitecan in SCLC	<i>Erminia Massarelli</i>
10:03 AM	Sacituzumab tirumotecan plus pembrolizumab (P) as first-line treatment for PD-L1-positive advanced NSCLC: phase 3 OptiTROP-Lung05 study.	<i>Natasha Leighl</i>
10:10 AM	DISCUSSION	

TARGETING ROS1/ RET/NRG FUSIONS AND MTAP DELETION

Corey Langer

10:25 AM	Adjuvant selpercatinib in surgically resected Ret fusion NSCLC	<i>Corey Langer</i>
10:32 AM	Taletrectinib: a next-generation ROS1 inhibitor	<i>Misako Nagasaka</i>
10:39 AM	Zidesamtinib, a ROS1 inhibitor in development for ROS1-rearranged advanced or metastatic NSCLC	<i>Elaine Shum</i>
10:46 AM	Outcomes from a retrospective analysis of lung cancer patients treated with zenocutuzumab	<i>Zhaohui Arter</i>
10:53 AM	MTAP deletion as a synthetic lethality approach in lung cancer	<i>Khaled Hassan</i>
11:00 AM	Development and current data for AMG 193, a PRMT5 inhibitor in development for MTAP-deleted cancer	<i>Matthew Lee</i>
11:07 AM	Update on LungMAP: recently opened arms	<i>Helen Ross</i>

11:14 AM **DISCUSSION**

NOVEL ADCs

Natasha Leighl

11:30 AM	Sigvotatug vedotin (SGNB6A) as an approach to taxane-naïve NSCLC	<i>Corey Langer</i>
11:37 AM	HLX43 — a novel PDL1-targeted ADC using PD-L1 as a therapeutic receptor to deliver cytotoxic payload	<i>Fred Hirsch</i>
11:44 AM	Initial early phase experience with an anti-PTK7 ADC for NSCLC and SCLC	<i>Asrar Alahmadi</i>
11:51 AM	Emiltatug ledadotin, a B7H-4-targeting ADC in adenoid cystic carcinoma	<i>Renata Ferrarotto</i>
11:58 AM	SEZ targeting ADC in SCLC (ABBV-706)	<i>Millie Das</i>
12:05 PM	DISCUSSION	

THURSDAY, JULY 9, 2026, AFTERNOON SESSIONS

12:20 PM	LUNCH POSTER SESSION	<i>Vinay Jain</i>
EMERGING RAS-TARGETING AGENTS (RAS ON/OFF, G12D, Q61) <i>Heather Wakelee</i>		
1:15 PM	Biology of RAS mutations in lung cancer	<i>Ravi Salgia</i>
1:22 PM	Mechanisms of resistance to KRAS inhibitors and how to overcome this resistance, including daraxonrasib	<i>Biagio Ricciuti</i>
1:29 PM	Daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC	<i>Joshua Sabari</i>
1:36 PM	Current clinical data for zoldonrasib, a KRAS G12D inhibitor, in previously treated NSCLC with KRAS G12D mutations	<i>Jonathan Riess</i>
1:43 PM	VS-7375, a KRAS G12D inhibitor in early clinical development	<i>Matthew Gumbleton</i>
1:50 PM	ERAS-0015, a pan-RAS molecular glue in advanced or metastatic solid tumors	<i>Erminia Massarelli</i>
1:57 PM	Initial experience with a novel pan-KRAS inhibitor (PF-07934040) in KRAS-mutant NSCLC	<i>Matthew Lee</i>
2:04 PM	Biology and treatment strategies for KRAS Q61H mutations in NSCLC	<i>Ferdinandos Skoulidis</i>
2:11 PM	DISCUSSION	
EXON 20 AND ATYPICAL EGFR MUTATIONS <i>Julia Rotow</i>		
2:30 PM	How to manage EGFR atypical mutations in NSCLC, including PACC mutations	<i>Julia Rotow</i>
2:37 PM	Update on sunvozertinib for the treatment of NSCLC with EGFR exon 20 mutations	<i>Zhaohui Arter</i>
2:44 PM	Zipalertinib for exon 20 and other challenging EGFR mutations in stage IV NSCLC	<i>Jacqueline Aredo</i>
2:51 PM	Silevertinib, and BH-30643, next-generation EGFR inhibitors	<i>Xiuning Le</i>
2:58 PM	DISCUSSION	
OPEN QUESTIONS IN RADIATION THERAPY <i>Steven Lin</i>		
3:15 PM	Timing of checkpoint therapy with radiation: What have we learned, and where are we going?	<i>James Urbanic</i>
3:22 PM	Role of chemoimmunotherapy before chemoradiotherapy for stage III unresectable NSCLC	<i>Aditya Juloori</i>
3:29 PM	Selecting patients who might benefit from local consolidation? Insights on the NRG trial	<i>Stephen Swisher</i>
3:36 PM	Identifying oligometastatic disease likely to benefit from radiation therapy	<i>Jillian Tsai</i>
3:43 PM	Sequencing of radiation and immune checkpoint inhibition in head and neck cancer: Lessons learned	<i>Jonathan Schoenfeld</i>
3:50 PM	The potential role for radiation in SCLC	<i>Gregory Videtic</i>
3:57 PM	DISCUSSION	
6:30 PM	WELCOME DINNER	

FRIDAY, JULY 10, 2026, MORNING SESSIONS

6:00 AM **BREAKFAST**

TARGETING HER2 AND HER3 IN NSCLC

John Heymach

6:30 AM	DESTINY-Lung02 - Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC	<i>John Heymach</i>
6:37 AM	Combination trials in design or ongoing: Zongertinib and HER2-directed strategies	<i>Urs Weber</i>
6:44 AM	Izalontamab brengitecan (EGFRxHER3 ADC) in advanced EGFR-Mutated NSCLC	<i>Sid Devarakonda</i>
6:51 AM	Patritumab deruxtecan: Where are we?	<i>Julia Rotow</i>
6:58 AM	DISCUSSION	

EGFR TARGETING BISPECIFICS IN IN HEAD AND NECK CANCER

Everett Vokes

7:15 AM	Addition of PD-1 to Cetuximab in Head and neck cancer	<i>Assuntina (Tina) Sacco</i>
7:22 AM	Amivantamab as a therapeutic approach to HNSCC	<i>TBD</i>
7:29 AM	Petosemtamab, an EGFR/LGR5 bispecific, in HNSCC	<i>Everett Vokes</i>
7:36 AM	Ficerafusp alfa, a bispecific antibody targeting EGFRxTGF- β , in HNSCC	<i>Assuntina (Tina) Sacco</i>
7:43 AM	REM-422, an mRNA degrader targeting MYB and current data in adenoid cystic carcinoma	<i>Renata Ferrarotto</i>
7:50 AM	DISCUSSION	

NEOADJUVANT AND ADJUVANT TRIALS WITH AGENTS TARGETING KRAS G12C MUTATIONS

Mara Antonoff

8:05 AM	Sequential versus concurrent KRAS inhibition + immune checkpoint inhibition for adjuvant treatment of KRAS G12C-mutated NSCLC	<i>Ferdinandos Skoulidis</i>
8:12 AM	The role of olomorasib in the perioperative setting for KRAS G12C-mutated NSCLC	<i>Timothy Burns</i>
8:19 AM	Findings from divarasib in the neoadjuvant setting for KRAS G12C NSCLC	<i>Jamie Chافت</i>
8:26 AM	Ongoing adjuvant divarasib trials in KRAS G12C early stage NSCLC	<i>Jay Lee</i>
8:33 AM	DISCUSSION	

TARGETING B7H3 IN SCLC

Sandip Patel

8:50 AM	Ifinatamab deruxtecan in previously treated ES-SCLC	<i>Lauren Byers</i>
8:57 AM	Emerging ADCs targeting B7H3 in lung cancer	<i>Millie Das</i>
9:04 AM	Emerging data for YL201, a B7H3-targeted ADC in development for lung cancer	<i>Jeff Petty</i>
9:11 AM	First-in-human regulatable B7H3 CAR T-cell therapy (SNP CAR)	<i>Allison Betof</i>
9:18 AM	DISCUSSION	
9:35 AM	BREAK	

SCREENING AND ENVIRONMENTAL ISSUES

Lawson Eng

9:45 AM	What is the role for early disease screening in nonsmokers with high-risk family history?	<i>Jamie Chافت</i>
9:52 AM	Familial clustering in lung cancer: a mixture of inherited predisposition and exposure	<i>Sulin Wu</i>
9:59 AM	Cancer in the nonsmoker: Challenges and opportunities in detection and screening	<i>Heather Wakelee</i>
10:06 AM	Organizing a screening program for nonsmokers at high risk for lung cancer	<i>Elaine Shum</i>
10:13 AM	Environmental pollution and wildfires and pathogenesis and outcomes in lung cancer	<i>Surbhi Singhal</i>
10:20 AM	Evaluation of geospatial particulate matter in Rhode Island and its link to increased lung cancer risks	<i>Hina Khan</i>
10:27 AM	A real-world registry of patients with ground glass opacities: Whom to watch and whom to treat?	<i>James Huang</i>
10:34 AM	DISCUSSION	

ADVANCES IN RADIATION TECHNOLOGY

Jonathan Schoenfeld

10:50 AM	Role of radiation in patients with multiple metastatic lesions who are getting active therapy	<i>Jillian Tsai</i>
10:57 AM	Optimizing hypofractionated radiation therapy for stage III NSCLC	<i>Percy Lee</i>
11:04 AM	Can we give single-dose SBRT to treat lung cancer?	<i>Gregory Videtic</i>
11:11 AM	What is the current role for protons in current lung and thoracic tumors?	<i>James Urbanic</i>
11:18 AM	Hafnium oxide nanoparticle as radiation sensitizers	<i>Steven Lin</i>
11:25 AM	Central disease SBRT with MRI-guided radiation for NSCLC	<i>Percy Lee</i>
11:32 AM	Biology-guided radiation therapy for lung cancer	<i>Henry Park</i>
11:39 AM	Tumor treating fields (TTF/Optune Lua, Novocure)	<i>Corey Langer</i>
11:46 AM	DISCUSSION	

FRIDAY, JULY 10, 2026, AFTERNOON SESSIONS

12:05 PM	WORKING LUNCH SESSION : INDUSTRY PIPELINE PRESENTATIONS	Vinay Jain
12:25 PM	Amgen	TBD
12:35 PM	BioNTech	Claudia-Nanette Gann
12:45 PM	Nuvalent	TBD
12:55 PM	Nuvation Bio	TBD
1:05 PM	Gilead	TBD
SYNERGISTIC AGENTS WITH CHECKPOINT INHIBITORS Valsamo Anagnostou		
1:20 PM	The biological rationale for targeting CTLA4 in NSCLC patients with STK11 mutations	Biagio Ricciuti
1:27 PM	Ivonescimab: Ongoing Trials in NSCLC	Xiuning Le
1:34 PM	BNT324 + Punitamig (BNT327) combination in advanced lung cancer	Mehmet Altan
1:41 PM	ATR inhibitor Ceralasertib (C) + durvalumab (D) after anti-PD-(L)1 therapy	John Heymach
1:48 PM	Genomic markers of metastasis and metastatic sites in NSCLC	Brendan Knapp
1:55 PM	DISCUSSION	
MOLECULAR TARGETS IN SCLC Misty Shields		
2:10 PM	Genomics of chemotherapy and chemo+IO resistance in SCLC	Triparna Sen
2:17 PM	A retrospective analysis of 70 SCLC patients with Lambert-Eaton Syndrome and its impact on treatment efficacy	Michael Kelley
2:24 PM	Tazemetostat with topotecan and pembrolizumab in R/R SCLC	Zhonglin Hao
2:31 PM	The potential role of SMARCA2/4 as a therapeutic target for SCLC	Matthew Oser
2:38 PM	DISCUSSION	
OTHER TARGETS Mary Jo Fidler		
2:55 PM	p53 reactivators to improve treatment options	Misty Shields
3:02 PM	Bispecific for MUC-16 Ubamatamab +/- REGN7075 in previously treated NSCLC	Mehmet Altan
3:09 PM	Chitinase-3-like protein 1 (CHI3L1) inhibitor as a potential treatment for lung cancer	Hina Khan
3:16 PM	Early data for a bispecific targeting MUC1xCD3	Mary Jo Fidler
3:23 PM	Intratumoral HA3 oncolytic virus for overcoming immune resistance in relapsed/refractory metastatic NSCLC	Jun Zhang
3:30 PM	Using RipTAC technology to drug undruggable targets	Josh Bauml
3:37 PM	DISCUSSION	

SATURDAY, JULY 11, 2026, MORNING SESSIONS

6:00 AM BREAKFAST

PATIENT QUALITY OF LIFE

Ken Culver

6:30 AM	Palliative care as an essential component of patient care in the advanced disease setting	Fionnuala Crowley
6:37 AM	Gaps in knowledge: Bridging the gaps including identifying duration of treatment and contribution of components	Heather Wakelee
6:44 AM	Optimizing approaches to treating and preventing cancer cachexia, Ponesemab (PF-06946860): A GDF-15 antibody	Mary Jo Fidler
6:51 AM	Role of pulmonary rehabilitation in optimizing quality of life in metastatic NSCLC survivors	Melinda Hsu
6:58 AM	DISCUSSION	

NEUROENDOCRINE CARCINOMAS

Misty Shields

7:15 AM	Defining neuroendocrine carcinoma as a pathologic entity and optimizing treatment approaches	Jeff Petty
7:22 AM	Molecular profiling of pulmonary large cell neuroendocrine carcinoma	Umit Tapan
7:29 AM	Pathogenesis and clinical presentation for invasive mucinous adenocarcinoma	Matthew Gumbleton
7:36 AM	Perioperative strategies, including obixtamig, a DLL3xCD3 T-cell engager, in high-grade neuroendocrine carcinoma	Jay Lee
7:43 AM	A biomarker-driven trial design for neuroendocrine carcinoma (PD-1 + LAG-3)	Abdul Rafeh Naqash
7:50 AM	Extrathoracic NET: Current data and treatment approaches	Triparna Sen
7:57 AM	DISCUSSION	

VACCINES AND CELLULAR THERAPY AND ONCOLYTIC VIRUS

Matthew Gumbleton

8:15 AM	mRNA vaccines boosting cancer immunotherapy by activating the immune system, with early evidence of improved outcomes	Steven Lin
8:22 AM	Engineered TIL therapy for NSCLC using Obsidian Therapeutics' platform	Allison Betof
8:29 AM	BNT116: mRNA vaccine targeted tumor associated antigens	TBD
8:36 AM	The potential role for RAS vaccines for eliminating MRD in KRAS-mutated patients	Ferdinand Skoulidis
8:43 AM	Evidence for an intratumoral HA3 oncolytic virus for overcoming immune resistance in relapsed/refractory metastatic NSCLC	Jun Zhang
8:50 AM	DISCUSSION	

MESOTHELIOMA

Matthew Bott

9:05 AM	Emerging surgical approaches to mesothelioma	Marc de Perrot
9:12 AM	Using SW-682 to target YAP-TEAD and the Hippo pathway as a treatment approach for mesothelioma	Sandip Patel
9:19 AM	VT3989 and SW-682: TEAD as a therapeutic target in mesothelioma	Arjan Gower
9:26 AM	SynKIR-110 mesothelin KIR-CAR T for mesothelioma	Mehmet Altan
9:33 AM	Cellular therapies in development for lung cancer and mesothelioma targeting EGFR and mesothelin (A2B694 and A2B395)	Antonious Hazim
9:40 AM	Evidence for tumor treating fields in progressing mNSCLC and mesothelioma	Jun Zhang
9:47 AM	DISCUSSION	

GENOMICS/EPIGENOMICS/PROTEOMICS/METABOLOMICS

Ravi Salgia

10:05 AM	Circulating giant cells that may drive metastasis	Steven Lin
10:12 AM	Transcriptomic evaluation of the genomics of relapse in SCLC	Brendan Knapp
10:19 AM	Biomarker-driven age assessment to expand enrollment of older adults	Surbhi Singhal
10:26 AM	DISCUSSION	

AI AND MACHINE LEARNING

Sandip Patel

10:40 AM	Digital twin AI foundation model for lung cancer	John Heymach
10:47 AM	An AI-based approach to guide repurposing of treatments for tumors resistant to a prior targeted therapy	Vivek Behera
10:54 AM	Machine learning technologies to predict and detect myocarditis	Abdul Rafeh Naqash
11:01 AM	Using AI to score radiological responses in lung cancer trials	Dhruv Bansal
11:08 AM	AI/ML integration into genomic and clinical datasets to detect signals missed by conventional review	Sid Devarakonda
11:15 AM	DISCUSSION	

PREDICTING ICI RESPONSE AND NOVEL SYNERGISTIC AGENTS

Natasha Leighl

11:30 AM	Using ctDNA to predict patients likely to benefit from post-surgical immune checkpoint therapy	Heather Wakelee
11:37 AM	Spatial biology approaches to determine probability of response to immune checkpoint inhibitors for NSCLC	Vivek Behera
11:44 AM	Impact of antibiotic use in ICI efficacy	Lawson Eng
11:51 AM	Progress in predicting response to checkpoint inhibitors using transcriptomic profiling	Dhruv Bansal
11:58 AM	Translational biomarker pipeline for TIL patients — single-cell TCR-seq, 57-color flow cytometry, and spatial transcriptomics (Xenium)	Allison Betof
12:05 PM	DISCUSSION	